Eli Lilly to Acquire Morphic Holding for $3.2 Billion to Expand Immunology Pipeline
Eli Lilly and Company is set to acquire Morphic Holding, Inc. (NASDAQ: MORF), a biopharmaceutical company based in Waltham, MA, known for developing oral integrin therapies for serious chronic diseases. Lilly will commence a tender offer to acquire all outstanding shares of Morphic for $57 per share in cash, totaling approximately $3.2 billion. The transaction … Read more